These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

392 related articles for article (PubMed ID: 31006056)

  • 21. Multiple Criteria Decision Analysis for HTA across four EU Member States: Piloting the Advance Value Framework.
    Angelis A; Linch M; Montibeller G; Molina-Lopez T; Zawada A; Orzel K; Arickx F; Espin J; Kanavos P
    Soc Sci Med; 2020 Feb; 246():112595. PubMed ID: 31874372
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Incorporating MCDA into HTA: challenges and potential solutions, with a focus on lower income settings.
    Marsh K; Thokala P; Youngkong S; Chalkidou K
    Cost Eff Resour Alloc; 2018; 16(Suppl 1):43. PubMed ID: 30455602
    [TBL] [Abstract][Full Text] [Related]  

  • 23. TESTING MULTI-CRITERIA DECISION ANALYSIS FOR MORE TRANSPARENT RESOURCE-ALLOCATION DECISION MAKING IN COLOMBIA.
    Castro Jaramillo HE; Goetghebeur M; Moreno-Mattar O
    Int J Technol Assess Health Care; 2016 Jan; 32(4):307-314. PubMed ID: 27691990
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Health technology assessment of medical devices: What is different? An overview of three European projects.
    Schnell-Inderst P; Mayer J; Lauterberg J; Hunger T; Arvandi M; Conrads-Frank A; Nachtnebel A; Wild C; Siebert U
    Z Evid Fortbild Qual Gesundhwes; 2015; 109(4-5):309-18. PubMed ID: 26354131
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Multiple Criteria Decision Analysis for Health Care Decision Making--An Introduction: Report 1 of the ISPOR MCDA Emerging Good Practices Task Force.
    Thokala P; Devlin N; Marsh K; Baltussen R; Boysen M; Kalo Z; Longrenn T; Mussen F; Peacock S; Watkins J; Ijzerman M
    Value Health; 2016 Jan; 19(1):1-13. PubMed ID: 26797229
    [TBL] [Abstract][Full Text] [Related]  

  • 26. International experiences in multicriteria decision analysis (MCDA) for evaluating orphan drugs: a scoping review.
    Lasalvia P; Prieto-Pinto L; Moreno M; Castrillón J; Romano G; Garzón-Orjuela N; Rosselli D
    Expert Rev Pharmacoecon Outcomes Res; 2019 Aug; 19(4):409-420. PubMed ID: 31210065
    [No Abstract]   [Full Text] [Related]  

  • 27. [Multi-criteria decision analysis for health technology resource allocation and assessment: so far and so near?].
    Campolina AG; Soárez PC; Amaral FVD; Abe JM
    Cad Saude Publica; 2017 Oct; 33(10):e00045517. PubMed ID: 29091169
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Multi-Criteria Decision Analysis (MCDA) Models in Health Technology Assessment of Orphan Drugs-a Systematic Literature Review. Next Steps in Methodology Development?
    Baran-Kooiker A; Czech M; Kooiker C
    Front Public Health; 2018; 6():287. PubMed ID: 30374435
    [No Abstract]   [Full Text] [Related]  

  • 29. Multi-criteria Decision Analysis Software in Healthcare Priority Setting: A Systematic Review.
    Moreno-Calderón A; Tong TS; Thokala P
    Pharmacoeconomics; 2020 Mar; 38(3):269-283. PubMed ID: 31820294
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Potential impact of the implementation of multiple-criteria decision analysis (MCDA) on the Polish pricing and reimbursement process of orphan drugs.
    Kolasa K; Zwolinski KM; Kalo Z; Hermanowski T
    Orphanet J Rare Dis; 2016 Mar; 11():23. PubMed ID: 26965710
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Disinvestment in healthcare: an overview of HTA agencies and organizations activities at European level.
    Calabrò GE; La Torre G; de Waure C; Villari P; Federici A; Ricciardi W; Specchia ML
    BMC Health Serv Res; 2018 Mar; 18(1):148. PubMed ID: 29490647
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Are adverse effects incorporated in economic models? An initial review of current practice.
    Craig D; McDaid C; Fonseca T; Stock C; Duffy S; Woolacott N
    Health Technol Assess; 2009 Dec; 13(62):1-71, 97-181, iii. PubMed ID: 20018146
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Step Toward the Development of the First National Multi-Criteria Decision Analysis Framework to Support Healthcare Decision Making in Saudi Arabia.
    Al-Jedai A; Almudaiheem H; Alruthia Y; Althemery A; Alabdulkarim H; Ojeil R; Alrumaih A; AlGhannam S; AlMutairi A; Hasnan Z
    Value Health Reg Issues; 2024 May; 41():100-107. PubMed ID: 38306770
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The effectiveness of internet-based e-learning on clinician behavior and patient outcomes: a systematic review protocol.
    Sinclair P; Kable A; Levett-Jones T
    JBI Database System Rev Implement Rep; 2015 Jan; 13(1):52-64. PubMed ID: 26447007
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Making Good Decisions in Healthcare with Multi-Criteria Decision Analysis: The Use, Current Research and Future Development of MCDA.
    Mühlbacher AC; Kaczynski A
    Appl Health Econ Health Policy; 2016 Feb; 14(1):29-40. PubMed ID: 26519081
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An Evidence Framework for Off-Patent Pharmaceutical Review for Health Technology Assessment in Emerging Markets.
    Brixner D; Kaló Z; Maniadakis N; Kim K; Wijaya K
    Value Health Reg Issues; 2018 Sep; 16():9-13. PubMed ID: 29605800
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Multiple Criteria Decision Analysis for Health Care Decision Making--Emerging Good Practices: Report 2 of the ISPOR MCDA Emerging Good Practices Task Force.
    Marsh K; IJzerman M; Thokala P; Baltussen R; Boysen M; Kaló Z; Lönngren T; Mussen F; Peacock S; Watkins J; Devlin N;
    Value Health; 2016; 19(2):125-37. PubMed ID: 27021745
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Stakeholder perception of pharmaceutical value: A multicriteria decision analysis pilot case study for value assessment in the United States.
    Mendola ND; Oehrlein E; Perfetto EM; Westrich K; McQueen RB
    J Manag Care Spec Pharm; 2022 Oct; 28(10):1190-1196. PubMed ID: 36125060
    [No Abstract]   [Full Text] [Related]  

  • 39. Health Technology Assessment and Appraisal of Therapies for Rare Diseases.
    Iskrov G; Miteva-Katrandzhieva T; Stefanov R
    Adv Exp Med Biol; 2017; 1031():221-231. PubMed ID: 29214575
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Harnessing ecosystem models and multi-criteria decision analysis for the support of forest management.
    Wolfslehner B; Seidl R
    Environ Manage; 2010 Dec; 46(6):850-61. PubMed ID: 20024654
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.